ログインで組織・契約価格をご覧ください。
サイズを選択してください
この商品について
実験式（ヒル表記法）:
C14H10Cl2NNaO2
CAS番号:
分子量:
318.13
NACRES:
NA.24
PubChem Substance ID:
UNSPSC Code:
41116107
MDL number:
InChI
1S/C14H11Cl2NO2.Na/c15-10-5-3-6-11(16)14(10)17-12-7-2-1-4-9(12)8-13(18)19;/h1-7,17H,8H2,(H,18,19);/q;+1/p-1
SMILES string
[Na+].[O-]C(=O)Cc1ccccc1Nc2c(Cl)cccc2Cl
InChI key
KPHWPUGNDIVLNH-UHFFFAOYSA-M
grade
pharmaceutical primary standard
API family
diclofenac
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
Gene Information
human ... PTGS1(5742), PTGS2(5743)
類似した製品をお探しですか？ 訪問 製品比較ガイド
General description
Diclofenac sodium is a sodium salt of diclofenac, a non-steroidal anti-inflammatory drug (NSAID). It prevents the synthesis of prostaglandin involved in pain, inflammation, and fever by inhibiting the cyclooxygenase enzyme activity.
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Diclofenac sodium USP reference standard suitable for use in specified USP compendial quality tests and assays.
Also used to prepare acid stage standard, standard, standard stock, sensitivity, and system suitability solution for the assay, impurity analysis, identification, and performance test by using liquid chromatography coupled with UV detector according to the given below monographs of United States Pharmacopeia (USP):
Also used to prepare acid stage standard, standard, standard stock, sensitivity, and system suitability solution for the assay, impurity analysis, identification, and performance test by using liquid chromatography coupled with UV detector according to the given below monographs of United States Pharmacopeia (USP):
- Diclofenac Sodium
- Diclofenac Sodium Delayed-Release Tablets
- Diclofenac Sodium Extended-Release Tablets
- Diclofenac Sodium Topical Solution
- Diclofenac Sodium and Misoprostol Delayed-Release Tablets
Biochem/physiol Actions
標準的なNSAIDかつシクロオキシゲナ-ゼ (COX) 阻害剤です。主要代謝産物は4´-ヒドロキシジクロフェナクおよび5´-ヒドロキシジクロフェナクです。CYP2C9に特異的な基質として用いられてきました。
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
signalword
Danger
hcodes
Hazard Classifications
Acute Tox. 3 Oral - Aquatic Chronic 2 - Repr. 2 - STOT RE 1
保管分類
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
1188800-200MG:
jan
Diclofenac Sodium
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 42(4), 1347-1347 (2020)
Adaptation of a color reaction for spectrophotometric determination of diclofenac sodium and piroxicam in pure form and in pharmaceutical formulations
El-Didamony, AM and Amin, AS
Analytical Letters, 37(6), 1151-1162 (2004)
Diclofenac Sodium Extended-Release Tablets
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 40(6), 1350-1350 (2016)
Diclofenac Sodium and Misoprostol Delayed-Release Tablets
USP43-NF38: United States Pharmacopeia and National Formulary
United States Pharmacopeia, 43(5), 1353-1353 (2023)
Development and implication of a capillary electrophoresis methodology for ciprofloxacin, paracetamol and diclofenac sodium in pharmaceutical formulations and simultaneously in human urine samples
Solangi AR, et al.
Pakistan Journal of Pharmaceutical Sciences, 24(4), 539-544 (2011)
ライフサイエンス、有機合成、材料科学、クロマトグラフィー、分析など、あらゆる分野の研究に経験のあるメンバーがおります。.
製品に関するお問い合わせはこちら（テクニカルサービス）